UroGen Pharma (URGN) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Join SI Premium – FREE
UroGen Pharma (NASDAQ: URGN) reported Q4 EPS of ($1.22), $0.15 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $18.09 million versus the consensus estimate of $18.51 million.
For earnings history and earnings-related data on UroGen Pharma (URGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can JetBlue still avoid bankruptcy? Analysis says yes, but it won’t be easy
- Kforce (KFRC) Tops Q3 EPS by 2c; offers guidance
- Whirlpool (WHR) Misses Q3 EPS by $1.25
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
